BeiGene takes a new approach to a hot target
Meanwhile Bristol’s Orum-originated project goes into the clinic, and Miltenyi looks to challenge Syndax and Kura.
Immatics’ PRAME gift keeps on giving
The company dribbles out more data on IMA203, and the numbers head in the right direction.
Immatics builds on its PRAME success
PRAME has become a hot target for Immatics, which is now clinically progressing two different modalities against this antigen.
